These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 30918400)

  • 21. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
    Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
    Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.
    Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
    Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
    Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
    Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS: feeding pancreatic cancer proliferation.
    Bryant KL; Mancias JD; Kimmelman AC; Der CJ
    Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.
    Brambillasca S; Cera MR; Andronache A; Dey SK; Fagá G; Fancelli D; Frittoli E; Pasi M; Robusto M; Varasi M; Scita G; Mercurio C
    Biomed Pharmacother; 2024 Aug; 177():116991. PubMed ID: 38906021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.
    Michalopoulou E; Auciello FR; Bulusu V; Strachan D; Campbell AD; Tait-Mulder J; Karim SA; Morton JP; Sansom OJ; Kamphorst JJ
    Cell Rep; 2020 Feb; 30(8):2729-2742.e4. PubMed ID: 32101748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling.
    De La O JP; Murtaugh LC
    Cell Cycle; 2009 Jun; 8(12):1860-4. PubMed ID: 19440048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic KRAS signalling in pancreatic cancer.
    Eser S; Schnieke A; Schneider G; Saur D
    Br J Cancer; 2014 Aug; 111(5):817-22. PubMed ID: 24755884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
    Genovese G; Carugo A; Tepper J; Robinson FS; Li L; Svelto M; Nezi L; Corti D; Minelli R; Pettazzoni P; Gutschner T; Wu CC; Seth S; Akdemir KC; Leo E; Amin S; Molin MD; Ying H; Kwong LN; Colla S; Takahashi K; Ghosh P; Giuliani V; Muller F; Dey P; Jiang S; Garvey J; Liu CG; Zhang J; Heffernan TP; Toniatti C; Fleming JB; Goggins MG; Wood LD; Sgambato A; Agaimy A; Maitra A; Roberts CW; Wang H; Viale A; DePinho RA; Draetta GF; Chin L
    Nature; 2017 Feb; 542(7641):362-366. PubMed ID: 28178232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ciliogenesis and Hedgehog signalling are suppressed downstream of KRAS during acinar-ductal metaplasia in mouse.
    Bangs FK; Miller P; O'Neill E
    Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32571902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.
    Than MT; O'Hara M; Stanger BZ; Reiss KA
    Mol Cancer Ther; 2024 Oct; 23(10):1378-1388. PubMed ID: 39118358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ANGPTL4 accelerates KRAS
    Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
    Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
    Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
    Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.